VP Sales EMEA   |   UK/EU   |   3rd January 2023

Causaly appoints Andrew Dalton as VP Sales EMEA


Founded in 2018 and headquartered in London, Causaly is a disruptive AI SaaS solution for Pharmaceutical and Biotech organisations.

It empowers researchers and decision makers to quickly find evidence and generate insights from millions of documents that are critical in the drug discovery, safety and commercialisation process. The company has developed a knowledge platform that reads text like humans, understanding syntax and semantics, to create a high precision causal knowledge graph and applies machine learning to surface new knowledge. It has been proven that Causaly can increase research productivity by between 5x – 10x and help organisations generate unconventional insights, therefore improving innovation cycles in drug development. Customers can also greatly decrease the onboarding time of staff in different therapeutic areas, accelerate research schedules, improve time-to-insight significantly and ultimately help companies to reduce time-to-decision.

Causaly has raised several rounds of funding from an excellent syndicate of investors that incudes Index Ventures, Pentech and Marathon.

Andrew has over a decades’ experience of selling software and services to the life sciences and pharmaceutical market. This has been gained in both major organisation such as Hitachi Medical Systems and GE Healthcare, as well as high quality scaleups such as Sensyne Health and ArisGlobal. He joins to take over all responsibility in the EMEA commercial organisation.

Commenting on the hire, Sebastian Kayll stated "Having already hired Chris Tunnell into the SVP Global Sales position in Causaly, we are delighted to continue our relationship and bring Andrew in as his EMEA Sales Lead. I have no doubt that the pair of them will be a powerful combination and that Causaly will become a market leader in AI for the drug discovery market".

For more information, please visit www.causaly.com


Assignment conducted by:

Keep up-to-date

Sign up to receive our regular updates and newsletters, and see more of what we've been working on.